Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Cathay General Hospital maintains 1 pending office action in the Biotechnology & Pharmaceuticals technology area. The prosecution is currently confined to 1 distinct examiner and 1 distinct art unit, which suggests a very specific focus for their active intellectual property matters. In the highly regulated biotechnology sector, having a single pending action means the hospital's current patent office engagement is extremely targeted. This concentration allows for a deep focus on the specific technical hurdles presented by the current examiner but offers no alternative paths for portfolio growth through other active applications.
KOSAR, ANDREW D is the busiest examiner for the portfolio, with 1 busiest examiner pending action. This single action accounts for the total volume of pending office actions, meaning the hospital's current success in this area depends on the outcome of this specific examiner's evaluation. The practitioner's strategy must be finely tuned to this examiner's specific feedback, as there are no other pending actions to provide broader context or alternative opportunities for allowance. The hospital's immediate patent trajectory is thus defined by the progress of this individual application under this specific examiner.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KOSAR, ANDREW D | 1 | 41.9% | +31.9% |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18413542 | METHOD FOR TREATMENT OR IMPROVEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY BY LUMICHROME | KOSAR, ANDREW D | — |
| Art Unit | Apps |
|---|---|
| 1625 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18413542 | METHOD FOR TREATMENT OR IMPROVEMENT OF NON-ALCOHOLIC FATTY LIVER DISEASE AND OBESITY BY LUMICHROME | KOSAR, ANDREW D | 1625 | §103 | Non-Final OA | — | Pending | Jan 16, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialCathay General Hospital has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Andrew D Kosar has the most, with 1 of Cathay General Hospital's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
